Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia

AstraZeneca

25 January 2021 - 88% of patients on Calquence remained free of disease progression after 12 months vs. 68% for comparators.

AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma).

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Japan